Overview
- The U.S. Food and Drug Administration has approved Orzeyful (oveporexton) for adults with narcolepsy type 1, granting marketing authorization to Takeda Pharmaceuticals America.
- Orzeyful is an oral tablet taken twice daily that works as an orexin receptor agonist to replace the missing orexin signal tied to the condition.
- Two Phase 3 trials reported that patients taking Orzeyful experienced longer daytime wakefulness, less daytime sleepiness, fewer cataplexy episodes, and improved attentiveness compared with results seen with current therapies.
- Clinicians and patients see the drug as appealing because it targets the underlying biology rather than only treating symptoms, and it could avoid some misuse risks linked to stimulants and sodium oxybates.
- Key open questions remain about long-term safety, real-world effectiveness, pricing, and access, and regulators and researchers say the approval validates a drug class that may drive broader neurologic studies.